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Abstract We have cloned the murine CCR6 receptor and its
ligand, the L-chemokine mMIP-3K. Calcium mobilization assays
performed with mCCR6 transfectants showed significant re-
sponses upon addition of mMIP-3K. Murine MIP-3K RNA is
expressed in thymus, small intestine and colon, whereas mCCR6
RNA is expressed in spleen and lymph nodes. RT-PCR analysis
of FACS-sorted lymphoid and antigen presenting cell subsets
showed mCCR6 expression mainly in B cells, CD8^ splenic
dendritic cells and CD4+ T cells. The cloning and functional
characterization of the mCCR6 and mMIP-3K will allow the
study of the role of these proteins in mouse models of
inflammation and immunity.
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1. Introduction
Chemokines are a group of small chemoattractant cyto-
kines that play a key role in the tra⁄cking of in£ammatory
cells [1,2]. The presence or absence of an intervening amino
acid residue between two conserved cysteines in the N-termi-
nal region de¢nes the two main subfamilies of chemokines
that are called K (or CXC) and L (or CC), respectively. The
number of described chemokines is continually increasing and
recently the existence of two more subfamilies of chemokines
(C and CX3C) has been postulated [3^5]. A speci¢c subset of
the superfamily of seven transmembrane, G protein-coupled
receptors are the mediators of the actions of chemokines on
their target cells. Many human chemokine receptors have al-
ready been identi¢ed and their ligand binding characteristics
have been established. Five of these receptors (CXCR1^
CXCR5) are speci¢c for K-chemokines [6,7], while receptors
CCR1^CCR10 bind L-chemokines [1,2,8]. The Du¡y red
blood antigen, also known as Du¡y antigen receptor for
chemokines (DARC), is able to bind both K- and L-chem-
okines [9]. In addition, very recently CX3CR1, the receptor
for fractalkine [10] and XCR1, the receptor for lymphotactin
[11] have been reported.
With few exceptions, the chemokine system of receptors
and ligands is characterized by promiscuity. Most chemokine
receptors are able to bind several chemokines and di¡erent
chemokines interact with more than one receptor. One of
these exceptions is CCR6, a receptor that we and others ini-
tially described as orphan [12,13], and which was then re-
ported to be the speci¢c receptor for a L-chemokine independ-
ently identi¢ed under the names MIP-3K/LARC/Exodus [14^
20]. Besides this high speci¢city for a single ligand, two other
features make CCR6 di¡erent from other L-chemokine recep-
tors. First, its expression is quite restricted to lymphocytes
and dendritic cells (DC), and secondly, the gene encoding
CCR6 is located on chromosome 6 [12^17]; all the other
mapped L-chemokine receptor genes are clustered on chromo-
some 3 [8,21,22]. Concerning MIP-3K, no other interaction
with chemokine receptors has been found so far, apart from
that with CCR6. Also, the MIP-3K gene is placed on chro-
mosome 2 instead of chromosome 17, where most CC chemo-
kine genes are located [14]. The singularity of CCR6 and its
ligand prompted us to clone their murine counterparts, with
the purpose of taking advantage of murine models to study
the role of this unique receptor/ligand pair as potential regu-
lators of the migration and recruitment of antigen presenting
and immunocompetent cells during in£ammatory and immu-
nological responses.
In this paper we report the cloning of two murine genes
whose predicted amino acid sequences are highly homologous
to those of hCCR6 or hMIP-3K, respectively. Data showing
the activation of mCCR6 transfected cells upon binding of
mMIP-3K or hMIP-3K, and the constitutive RNA expression
of these genes in tissues as well as in lymphoid and antigen
presenting cell subsets are also reported.
2. Materials and methods
2.1. Cells
Thymic and splenic DCs were puri¢ed as described [23]. An en-
riched DC preparation was obtained from a low density cell fraction
by immunomagnetic depletion after incubation with anti-CD3, anti-
CD4, anti-IL-2RK, anti-B220, anti-macrophage antigen F4/80, and
anti-granulocyte antigen Gr1. CD8 and CD83 DC subsets were
sorted as CD8 CD11c and CD83 CD11c cells, respectively, using
a FACSort cytometer (Becton Dickinson, Mountain View, CA, USA).
Langerhans cells were puri¢ed as described [24]. Ears were split into
dorsal and ventral halves, and incubated with 0.5% trypsin for 30 min
at 37‡C to allow the separation of the epidermal sheets, which were
cultured for 24 h with 100 ng/ml GM-CSF. After this culture period
most LCs were released to the culture medium and were subsequently
sorted as MHC class II CD11c cells. Peritoneal macrophages were
sorted as Mac-1 F4/80 cells from a peritoneal cell preparation.
Thymic B cells were isolated from a highly enriched thymic B cell
preparation obtained from a low density cell fraction by immunomag-
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netic depletion after incubation with anti-CD3, anti-CD4, anti-IL-
2RK, anti-macrophage antigen F4/80, and anti-granulocyte antigen
Gr1. B cells were then sorted as B220 MHC class II cells. B cells,
CD4 T cells and CD8 T cells were sorted from mesenteric lymph
node cell suspensions as B220 CD43 CD83, CD4 CD83 B2203
and CD8 CD43 B2203 cells, respectively. Double positive thymo-
cytes were sorted as CD4 CD8 cells. CD4 single positive thymo-
cytes were sorted as CD4 cells after depletion of CD8 thymocytes.
CD8 single positive thymocytes were sorted as CD8 cells. Pre-T
cells were sorted as CD43 CD83 CD25 cells after depletion of
CD4 and/or CD8 thymocytes. All the cell subsets were puri¢ed
from 5^7 weeks old female BALB/c mice. After reanalysis the sorted
cell populations had a purity of s 98%. Human embryonic kidney
293 cells were obtained from the ATCC and maintained in DMEM
supplemented with 10% FCS (Seralab) and antibiotics. Human and
murine CCR6 genes were cloned in pCIneo (Promega) and stable
transfectants were obtained after G418 selection of cells transfected
with the resulting plasmids by the calcium phosphate method, as
described [25].
2.2. Cloning of mCCR6
A set of degenerate oligonucleotides was designed based on the
conserved sequences in transmembrane domains (TM) 3 and 7 of
known chemokine receptors, and used to perform PCR ampli¢cations
as described elsewhere [12]. Using mouse genomic DNA as template,
PCR products obtained using primers (TM3) 5P-CTCCTGGCCTGY-
ATNTCNGTNGAYMGNTAY-3P and (TM7) 5P-GCCGATRAAN-
GCRTANATNATNGGRTTNASRCARCA-3P gave positive signals
in Southern blots with a TM3^TM7 hCCR6 probe. Based on the
sequence of this mouse DNA fragment, highly similar to the sequence
of the corresponding region in hCCR6, two speci¢c oligonucleotide
primers were designed (5P-ATCGTCCAGGCAACCAAATCTTTCC-
3P and 5P-CCGCAGTCACGAGGAGGACCATG-3P) and used to
PCR-screen a mouse genomic library in phage P1 (Genome Systems)
to obtain the complete coding sequence of mCCR6, that was found to
be contained within a 3.5-kbp HindIII-ScaI fragment from the pos-
itive clones obtained. To determine the 5P-end cDNA sequence of
mCCR6, a DNA sample from a mouse spleen cDNA library (Stra-
tagene) was used as template in PCR ampli¢cation experiments with
mCCR6-speci¢c and vector primers. An expression plasmid was ¢-
nally constructed using the pCIneo vector and a DNA fragment con-
taining the mCCR6 coding sequence 5P-£anked by an optimal Kozak
motif.
2.3. Cloning of mMIP-3K
One Wg of thymus poly(A) RNA was reverse transcribed in 25 Wl,
using the SuperScript II enzyme (Gibco-BRL) as indicated by the
supplier. One-tenth of this reaction was added to a 100-Wl PCR mix-
ture and ampli¢ed for 36 cycles (30 s/94‡C; 40 s/50‡C; 45 s/72‡C) with
5 units of Expand polymerase (Boehringer Mannheim) and the fol-
lowing oligonucleotides: 5P-ACTGGGTACCCAGCACTGAGCA-
GAT-3P and 5P-ATATGAATTCTTGGGCTGTGTCCAATTCCAT-
3P. The resulting DNA was treated with KpnI and EcoRI, cloned in
pBluescript KS and sequenced.
2.4. Chemokines
Recombinant human MIP-3K was purchased from PeproTech. Re-
combinant mouse TECK and 6Ckine were from RpD. The thrombin
receptor agonist peptide SFLLR-amide was purchased from Bachem.
Based on the sequence predicted for the mature protein, murine MIP-
3K was synthesized on a fully automated peptide synthesizer (Applied
Biosystems 430) by Fmoc-chemistry according to standard protocols.
Purity and composition of folded and unfolded polypeptides has been
con¢rmed by HPLC on a C-18 Nucleosil 120 analytical column (Trac-
er), by amino acid analysis using a Beckman 6300 amino acid ana-
lyzer, and by mass spectrometry using an ion-trap mass spectrometer
model LCQ, with an electrospray interface (Finnigan, ThermoQuest,
USA). Folding and disul¢de bridges formation of the HPLC products
has been carried out according to Clark-Lewis et al. [26].
2.5. Calcium mobilization studies
Calcium £uorometry on 293 transfectant cells was carried out with
indo-1 AM-loaded cells as described elsewhere [27]. Each measure was
done on 1-ml aliquots containing 3U106 cells. Additions of chemo-
kines were done in 10 Wl.
2.6. Analysis of gene expression
Total RNA from mouse tissues was extracted with Tri-reagent (Sig-
ma) following the instructions of the supplier. The RNA samples were
electrophoresed on a denaturing formaldehyde-agarose gel and blot-
ted onto Nylon Hybond N membranes. Pre-hybridization of the
membranes and hybridization with 32P-labeled probes (DNA frag-
ments containing the TM3^TM7 region of mCCR6, or the complete
coding sequence of mMIP-3K) were carried out in Rapid Hyb bu¡er
(Amersham) as recommended by the supplier. For RT-PCR analysis,
total RNA from FACS-sorted cell subpopulations was extracted and
reverse-transcribed as indicated above. Equal amounts of cDNA were
subjected to PCR ampli¢cation of mCCR6 using a forward primer
speci¢c to the untranslated 5P region (5P-CTGCAGTTCGAAGT-
CATC-3P) and a reverse primer speci¢c to the mCCR6 open reading
frame (5P-GTCATCACCACCATAATGTTG-3P) under the following
conditions: 15 s/94‡C; 15 s/59‡C; 45 s/72‡C.
3. Results
3.1. Cloning of mCCR6
We followed a degenerate PCR-based approach for the
cloning of the murine CCR6 gene, using oligonucleotide pairs
designed according to the conserved sequences in the trans-
membrane regions 3 and 7 of L-chemokine receptors. The
complete open reading frame of the gene was ¢rst established
by screening a mouse genomic DNA library in phage P1, and
then con¢rmed on a spleen cDNA library. Similarly to what
has been described for other members of the family, the com-
plete open reading frame of mCCR6 is contained within a
single exon of the gene. The situation is di¡erent in the
hCCR6 gene, where an intron interrupts the N-terminal cod-
ing sequence [15]. Nevertheless, when mCCR6 cDNA was
PCR-ampli¢ed with oligonucleotides covering the 5P-untrans-
lated region of the cDNA, DNA fragments of di¡erent size
were synthesized. The nucleotide sequence of some of these
DNA fragments was determined, showing that alternate splic-
ing at the 5P non-coding region had occurred; at least three
exons were identi¢ed in that DNA region (data not shown).
Similar mRNA variants have also been identi¢ed in CXCR1,
CXCR2, CXCR4, CCR2 and CCR5 [28^30]. The coding re-
gion of mCCR6 codes for a protein of 367 amino acid resi-
dues, whose predicted sequence is shown in Fig. 1, aligned
with those of hCCR6 and six murine L-chemokine receptors.
The similarity between the human and murine CCR6 sequen-
ces is 73.8% over the entire sequence, clearly higher than that
existing between mCCR6 and other murine L-chemokine re-
ceptors. In this regard, mCCR6 is more similar to mCCR4
(33.6%), as is also the case when hCCR6 is compared with the
other human L-chemokine receptors. The mCCR6 predicted
protein is 7 amino acid residues shorter than its human coun-
terpart, as a result of lacking 8 amino acids in the N-terminal
region and having one extra amino acid in the C-terminal
portion of the molecule. Murine CCR6 has two Asn residues
at positions 2 and 35 that are potential substrates for N-linked
glycosylation. In the case of hCCR6 two extra Asn residues
located in the ¢rst and third extracellular loops are also po-
tential sites for N-linked glycosylation [12].
3.2. Cloning of mMIP-3K
To clone the murine MIP-3K cDNA a PCR-based strategy
was followed. An oligonucleotide pair designed to amplify the
complete rat MIP-3K coding sequence (GenBank accession
number U90447) was used in a reaction in which murine
thymus cDNA was used as template. A DNA fragment with
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the expected size for a potential murine MIP-3K coding se-
quence was obtained and cloned. An open reading frame cod-
ing for a protein of 97 amino acids was identi¢ed, the ¢rst
27 residues corresponding to the predicted signal peptide
(MACGGKRLLFLALAWVLLAHLCSQAEAsASNYDCC-
L...). Sequencing of additional clones showed that a 3-bp
deletion in the 5P-region of the coding sequence was present
in 50% of them, thus predicting the absence of the Ala-28
residue. This indicates that such a variation may correspond
to the existence of an allelic polymorphism rather than a
change introduced in the PCR process. The sequence of the
predicted 97 amino acid murine protein is highly similar to
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Fig. 1. Amino acid sequence alignment of mCCR6 with hCCR6 and other murine L-chemokine receptors. Identical residues are marked with
grey boxes. Gaps are marked by dashes. TM, transmembrane domains. Potential N-glycosylation sites in the mCCR6 sequence are marked by
an asterisk.
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that of rat (65.8%) and human (65.3%) MIP-3K, thus suggest-
ing that we had indeed cloned the murine MIP-3K cDNA.
Fig. 2 shows a comparison of the predicted mature amino
acid sequences of the murine, rat and human MIP-3K pro-
teins, along with those of other murine L-chemokines. The
similarity of mMIP-3K to other murine chemokines is rela-
tively low, ranging from 28% to mExodus-2 (without consid-
ering the long C-terminal extension of mExodus) to 23% to
mRANTES. As hMIP-3K, mMIP-3K has the majority of the
conserved features of L-chemokines, including the four char-
acteristic cysteine residues, and amino acids Phe-39, Ala-49,
Trp-55 and Val-56. As predicted for the human and rat pro-
teins, mMIP-3K has Phe-23 and Ala-28, two positions that in
most L-chemokines are occupied by Tyr and Thr residues,
respectively.
3.3. MIP-3K-induced calcium mobilization in 293/CCR6 cells
For the functional characterization of mCCR6, murine
MIP-3K was chemically synthesized as described in Section
2. The interaction of mMIP-3K with mCCR6 was studied
by measuring changes in the intracellular calcium concentra-
tion of 293 cells stably transfected with an mCCR6 expression
plasmid (293/mCCR6). As shown in Fig. 3A (upper panel),
the addition of mTECK or m6Ckine, two recombinant mur-
ine L-chemokines, to 293/mCCR6 cells did not result in de-
tectable calcium mobilization whereas subsequent addition of
100 nM mMIP-3K induced a signi¢cant wave of calcium mo-
bilization. Murine MIP-3K did not induce a calcium wave in
control 293 cells transfected with the void pCIneo vector (293/
neo), whereas these cells were shown to be able to respond to
a di¡erent, non-chemokine peptide such as SFLLR-amide, for
which they express an endogenous receptor [31] (Fig. 3A, low-
er panel). The ability of mCCR6 to bind other mouse chemo-
kines such as mC10 and mMCP-5 was also tested with neg-
ative results (data not shown). The calcium response of 293/
mCCR6 cells to mMIP-3K was detectable at a chemokine
concentration as low as 0.1 nM, and was dose-dependent
(Fig. 3B), with a half-maximal e¡ect at 10 nM. The 293/
mCCR6 cells also responded to the addition of human
MIP-3K, and this stimulus partially reduced the ability of
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Fig. 3. MIP-3K-induced calcium mobilization on indo-1 AM-loaded 293 transfectant cells. A: Upper panel: 293/mCCR6 cells were stimulated
with 72 nM mTECK followed by 84 nM m6Ckine and 100 nM mMIP-3K. Lower panel: Control pCIneo-transfected 293 cells loaded similarly
with indo-1 AM were stimulated with 100 nM mMIP-3K followed by 27 WM SFLLR-amide, a molecule for which 293 cells express endogenous
receptors. B: Dose-response of 293/mCCR6 cells to mMIP-3K. C: 293/mCCR6 cells were sequentially stimulated with 10 nM hMIP-3K and
10 nM mMIP-3K as indicated. Arrows indicate the time of the additions. Variations in the relative £uorescence ratios re£ect changes in intra-
cellular free [Ca2].
Fig. 2. Amino acid sequence alignment of mMIP-3K with related L-chemokines. The sequences of the predicted mature proteins are shown.
Identical residues are marked with grey boxes. Gaps are marked by dashes. m, murine; h, human; r, rat. (*) The N-terminal extensions of
mC10-like (QITHATETKEVQSSLKAQQGLEIEM) and mC10 (GLIQEMEKEDRRYNPPII), and the C-terminal extensions of mTECK
(SDSQTERKKSNHMKSKVENPNSTSVRSATLGHPRMVMMPRKTNN), mEXODUS-2 (GCRKNRGTSKSGKKGKGSKGCKRTEQTQPS-
RG), and mJE (KTASALRSSAPLNVKLTRKSEANASTTFSTTTSSTSVGVTSVTVN) have been omitted in the alignment for clarity.
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the cells to respond to a subsequent addition of mMIP-3K ;
conversely, addition of mMIP-3K completely desensitized the
cells to a subsequent addition of hMIP-3K (Fig. 3C). 293 cells
stably transfected with a human CCR6 expression plasmid
also responded to mMIP-3K, although less e⁄ciently than to
hMIP-3K (data not shown). All these assays were also per-
formed using conditioned medium from 293 cells transfected
with an expression plasmid encoding mMIP-3K as a source of
natural mMIP-3K. The results (not shown) were essentially
identical to those obtained with synthetic mMIP-3K.
3.4. Tissue distribution of mCCR6 and mMIP-3K
The distribution of the mCCR6 and mMIP-3K messages
was studied by Northern blot of total RNA samples obtained
from di¡erent mouse tissues. As shown in Fig. 4, the expres-
sion of both genes is quite restricted. mCCR6 is mainly ex-
pressed in spleen and lymph nodes, where a transcript of
about 3.5 kb could be detected. Concerning the mMIP-3K
gene, a transcript of about 1 kb was detected in thymus, colon
and small intestine.
3.5. RT-PCR analysis of mCCR6 mRNA expression by
lymphoid and antigen presenting cell subsets
Fig. 5 shows the expression of mCCR6 analyzed by RT-
PCR of FACS-sorted lymphoid and antigen presenting cell
subsets. mCCR6 expression was found in B cells isolated
from the thymus, spleen and lymph nodes. Among thymo-
cytes mCCR6 appears to be expressed solely by CD4 single
positive cells, but not by CD25 CD43 CD83 pre-T cells,
CD4 CD8 double positive immature thymocytes or CD8
single positive cells. Correspondingly, mCCR6 mRNA was
found in CD4 but not CD8 peripheral T cells isolated
from the spleen or lymph nodes. With regard to DC, in addi-
tion to epidermal Langerhans cells, in the murine system
two main DC subtypes, di¡ering in their phenotype and
origin, have been de¢ned: CD8 lymphoid DC and CD83
DC [32]. Interestingly, whereas no mCCR6 mRNA was
found in epidermal Langerhans cells or in CD8 DC isolated
from the thymus or spleen, splenic CD83 DC were positive
for this chemokine receptor. Finally, no CCR6 expression
was detected in macrophages puri¢ed from the peritoneal
cavity.
4. Discussion
We have isolated and characterized mCCR6 and mMIP-3K,
two new members of the murine family of L-chemokine re-
ceptors and ligands. The predicted amino acid sequence of
mCCR6 corresponds to a protein of 367 amino acids, with
many of the conserved motifs of this family of receptors.
Concerning mMIP-3K, it is interesting to point out the exist-
ence of a unique Asp-Cys-Cys-Leu motif that is also shared
by hMIP-3K, hExodus-2 and mExodus-2, mTECK and the
mC10-like protein [33]. Actually, in computer-generated phy-
logenetic trees these chemokines are grouped together (not
shown). Presently it is not known whether this singularity
re£ects some common functional properties for this small
group of L-chemokines. We have detected the existence of a
mMIP-3K allele in which a 3-bp deletion is present, thus
predicting the absence of one alanine residue located in the
region around the signal peptide cleavage site. Since N-termi-
nal sequence variations in chemokines have been reported to
have important e¡ects in their activities and receptor binding
properties [34^37], it would be of interest to know whether the
di¡erent mMIP-3K polypeptides behave di¡erently. Interest-
ingly, a similar situation has also been reported for the hMIP-
3K gene, and, indeed, the long version of hMIP-3K has been
shown to be a better chemoattractant for T cells than a short
version of the protein, lacking the N-terminal Ala residue [16].
The fact that this structural dimorphism is conserved among
two evolutionarily distant species as mice and humans sug-
gests that it may have a relevant physiological role.
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Fig. 5. RT-PCR analysis of mCCR6 expression in FACS-sorted
lymphoid and antigen presenting cell subpopulations. Total RNA
was isolated from the indicated FACS-sorted cell subsets, reverse-
transcribed and subjected to PCR ampli¢cation using the mCCR6
speci¢c primers described in Section 2. In addition, ampli¢cations of
L-actin were performed with the di¡erent samples as an internal
control. A: Thymus cell types: 1, CD8 DC; 2, B cells; 3, CD43
CD83 double negative cells ; 4, CD4 CD8 double positive cells ;
5, CD8 CD43 single positive cells ; 6, CD83 CD4 single positive
cells. B: Mesenteric lymph node cell types: 1, B cells; 2, CD4 T
cells; 3, CD8 T cells. C: Spleen cell types: 1, CD83 DC; 2, CD8
DC; 3, B cells; 4, CD4 T cells; 5, CD8 T cells. D: Peritoneal
macrophages (MÖ), and Langerhans cells (LC).
Fig. 4. Tissue distribution of mCCR6 and mMIP-3K RNAs. North-
ern blotting experiments were performed with 10 Wg of total RNA
obtained from adult mouse tissues, and probed as described in Sec-
tion 2. Transcript size in kilobases is shown on the right. After the
transfer, methylene blue staining of the membranes was performed
to estimate the amount of RNA present in each lane (not shown).
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For the functional characterization of mCCR6 and mMIP-
3K, calcium £uorometry studies were performed on stable 293/
mCCR6 transfectant cells. The results showed that mCCR6
was able to transduce a strong calcium signal upon speci¢c
stimulation with chemically synthesized mMIP-3K. These data
support the conclusion that the cloned mCCR6 and mMIP-3K
indeed are both structural and functional homologs for
hCCR6 and hMIP-3K. Human MIP-3K was also able to stim-
ulate 293/mCCR6 cells, an interspecies crossreactivity that is
consistent with the high degree of homology between the ami-
no acid sequences of both chemokines (65.3%). Accordingly,
the stimulation of 293/mCCR6 cells with either murine or
human MIP-3K resulted in desensitization to a subsequent
stimulus with the other one. However, mMIP-3K was a
much more e⁄cient desensitizer to hMIP-3K than the con-
verse, suggesting that the crossreactivity of MIP-3K is limited.
Studies on hCCR6 transfected 293 cells also indicated a pref-
erence for its homolog ligand (data not shown). The study of
the potential role played by G proteins in the signal trans-
duction pathway of mCCR6 was approached by incubating
293/mCCR6 cells with or without pertussis or choleric toxins
prior to calcium £uorometry. No signi¢cant e¡ects were no-
ticed (data not shown). This contrasts with the behavior of
most chemokine receptors, which are sensitive to inhibition of
calcium signalling by pertussis toxin. However, the result is
consistent with the reported lack of e¡ect of pertussis toxin on
the hMIP-3K-induced stimulation of hCCR6-transfected 293
cells [15].
The constitutive tissue distribution of the mCCR6 RNA
seems to be restricted to spleen and lymph nodes, where a
transcript of about 3.5 kb is expressed. This pattern of tissue
expression is very similar to the one that we and others de-
scribed for hCCR6 [12^14]. Semi-quantitative RT-PCR anal-
ysis of mCCR6 expression revealed that this chemokine re-
ceptor is mainly expressed by B cells, CD83 splenic DC and
to a lesser extent by CD4 T cells. This restricted expression
of mCCR6 is in accordance with a recent report by Greaves et
al. [17] showing that hCCR6 was expressed by human DC
derived from CD34 cord blood precursors, but not by mono-
cyte-derived DC. With regard to the selective expression of
mCCR6 by CD83 DC and B cells, these data suggest a pos-
sible role of CCR6 in the recruitment and positioning of de-
¢ned subsets of lymphocytes and antigen presenting cells with-
in lymphoid organs. In this sense, it has been reported that in
the spleen CD83 DC are mainly located in the marginal zone
[38], where they co-localize with a subset of specialized mar-
ginal zone B cells. In addition, a lineage relationship between
B cells and CD83 DC has been proposed on the basis of the
phenotype of mice homozygous for an Ikaros null mutation,
in which T cells, CD8 DC and myeloid cells are produced,
but neither B cells, CD83 DC, nor NK cells are produced
[39].
In summary, we have cloned and functionally characterized
the mouse homologs of the human CCR6 and MIP-3K genes.
Based on its restricted mRNA expression and its selectivity
for ligand binding, CCR6 is presumed to be an important
target for modulating the immune response by controlling
the recruitment and positioning of lymphocytes and special-
ized antigen presenting cells within secondary lymphoid or-
gans. Our data show that the mouse and human genes have
similar characteristics, thus making the murine model a suit-
able one for studying the biological functions of this receptor
and its ligand. CCR6 as well as MIP-3K knockout mice are
being generated in our lab to help in these studies.
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